Polyclonal T‐cell antibody induction showed no clear difference in acute rejection compared with interleukin‐2 receptor antagonist induction (moderate certainty).
Polyclonal T‐cell antibody induction showed no clear difference in infection compared with interleukin‐2 receptor antagonist induction (moderate certainty).
Polyclonal T‐cell antibody induction showed no clear difference in bronchiolitis obliterans syndrome compared with interleukin‐2 receptor antagonist induction (moderate certainty).
Muromonab‐CD3 (T cell) showed no clear difference in failure of acute rejection reversal compared with other antibody (stratified by comparator) (moderate certainty).
Muromonab‐CD3 (T cell) showed no clear difference in recurrent rejection compared with other antibody (stratified by comparator) (moderate certainty).
Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: fever, chills, malaise after drug… compared with other antibody (stratified by comparator) (low certainty).
Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: neurological side effects compared with other antibody (stratified by comparator) (low certainty).